1. Morris SM Jr. Regulation of enzymes of urea and arginine synthesis. Annu Rev Nutr 1992; 12: 81-101. [
DOI:10.1146/annurev.nu.12.070192.000501] [
PMID]
2. Diez-Fernandez C, Häberle J. Targeting CPS1 in the treatment of Carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder. Expert Opin Ther Targets 2017; 21: 391-399. [
DOI:10.1080/14728222.2017.1294685] [
PMID]
3. Mian A, Lee B. Urea-cycle disorders as a paradigm for inborn errors of hepatocyte metabolism. Trends Mol Med 2002; 8: 583-589. [
DOI:10.1016/S1471-4914(02)02437-1]
4. Lee B. Urea cycle disorders: Management. UpToDate, Waltham, MA Wolters Kluwer Health. 2017.
5. Butler SL, Dong H, Cardona D, Jia M, Zheng R, Zhu H, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 2008; 88: 78-88. [
DOI:10.1038/labinvest.3700699] [
PMID]
6. Keskinen P, Siitonen A, Salo M. Hereditary urea cycle diseases in Finland. Acta Paediatr 2008; 97: 1412-1419. [
DOI:10.1111/j.1651-2227.2008.00923.x] [
PMID]
7. Nagata N, Matsuda I, Oyanagi K. Estimated frequency of urea cycle enzymopathies in Japan. Am J Med Genet 1991; 39: 228-229. [
DOI:10.1002/ajmg.1320390226] [
PMID]
8. Kurokawa K, Yorifuji T, Kawai M, Momoi T, Nagasaka H, Takayanagi M, et al. Molecular and clinical analyses of Japanese patients with carbamoylphosphate synthetase 1 (CPS1) deficiency. J Hum Genet 2007; 52: 349-354. [
DOI:10.1007/s10038-007-0122-9] [
PMID]
9. Díez-Fernández C, Hu L, Cervera J, Häberle J, Rubio V. Understanding carbamoyl phosphate synthetase (CPS1) deficiency by using the recombinantly purified human enzyme: effects of CPS1 mutations that concentrate in a central domain of unknown function. Mol Genet Metab 2014; 112: 123-132. [
DOI:10.1016/j.ymgme.2014.04.003] [
PMID]
10. Choi R, Park HD, Yang M, Ki CS, Lee SY, Kim JW, et al. Novel pathogenic variant (c. 580C> T) in the CPS1 gene in a newborn with carbamoyl phosphate synthetase 1 deficiency identified by whole exome sequencing. Ann Lab Med 2017; 37: 58-62. [
DOI:10.3343/alm.2017.37.1.58] [
PMID] [
PMCID]
11. Kutteh WH, Jaslow CR, Ke RW. Elevated homocysteine levels in women with recurrent pregnancy loss (RPL) are associated with A1298C mutations of methylenetetrahydrofolate reductase (MTHFR) in the absence of C677T mutations. Fertil Steril 2006; 86: S472-S473. [
DOI:10.1016/j.fertnstert.2006.07.1304]
12. Lange LA, Croteau-Chonka DC, Marvelle AF, Qin L, Gaulton KJ, Kuzawa CW, et al. Genome-wide association study of homocysteine levels in Filipinos provides evidence for CPS1 in women and a stronger MTHFR effect in young adults. Hum Mol Genet 2010; 19: 2050-2058. [
DOI:10.1093/hmg/ddq062] [
PMID] [
PMCID]
13. Van Spronsen F, Smit G, Erwich J. Inherited metabolic diseases and pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology 2005; 112: 2-11. [
DOI:10.1111/j.1471-0528.2004.00297.x] [
PMID]
14. Srinivasan RC, Zabulica M, Hammarstedt C, Wu T, Gramignoli R, Kannisto K, et al. A liver‐humanized mouse model of carbamoyl phosphate synthetase 1‐deficiency. J Inherit Metab Dis 2019: 1-10. [
DOI:10.1002/jimd.12067] [
PMID]
15. Funghini S, Thusberg J, Spada M, Gasperini S, Parini R, Ventura L, et al. Carbamoyl phosphate synthetase 1 deficiency in Italy: clinical and genetic findings in a heterogeneous cohort. Gene 2012; 493: 228-234. [
DOI:10.1016/j.gene.2011.11.052] [
PMID]
16. Lee J, Yang A, Kim J, Park H-D, Lee S, Lee S-K, et al. A Case of Carbamoyl Phosphate Synthetase 1 Deficiency with Novel Mutations in CPS1 Treated by Liver Cell Transplantation. Journal of The Korean Society of Inherited Metabolic disease 2017; 17: 31-37.
17. Burgard P, Kölker S, Haege G, Lindner M, Hoffmann GF. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders-review and meta-analysis of observational studies published over more than 35 years. J Inherit Metab Dis 2016; 39: 219-229. [
DOI:10.1007/s10545-015-9901-1] [
PMID]
18. McMillan HJ, Telegrafi A, Singleton A, Cho MT, Lelli D, Lynn FC, et al. Recessive mutations in ATP8A2 cause severe hypotonia, cognitive impairment, hyperkinetic movement disorders and progressive optic atrophy. Orphanet J Rare dis 2018; 13: 86. [
DOI:10.1186/s13023-018-0825-3] [
PMID] [
PMCID]